These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29218326)

  • 1. Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.
    Nanchahal J; Ball C; Swettenham J; Dutton S; Barber V; Black J; Copsey B; Dritsaki M; Taylor P; Gray A; Feldmann M; Lamb S
    Wellcome Open Res; 2017; 2():37. PubMed ID: 29218326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF (adalimumab) injection for the treatment of adults with frozen shoulder during the pain predominant stage protocol for a multi-centre, randomised, double blind, parallel group, feasibility trial.
    Hopewell S; Kenealy N; Knight R; Rangan A; Dutton S; Srikesavan C; Feldmann M; Lamb S; Nanchahal J
    NIHR Open Res; 2022; 2():28. PubMed ID: 37881307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.
    Nanchahal J; Ball C; Rombach I; Williams L; Kenealy N; Dakin H; O'Connor H; Davidson D; Werker P; Dutton SJ; Feldmann M; Lamb SE
    Lancet Rheumatol; 2022 Jun; 4(6):E407-E416. PubMed ID: 35949922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.
    Nanchahal J; Ball C; Davidson D; Williams L; Sones W; McCann FE; Cabrita M; Swettenham J; Cahoon NJ; Copsey B; Anne Francis E; Taylor PC; Black J; Barber VS; Dutton S; Feldmann M; Lamb SE
    EBioMedicine; 2018 Jul; 33():282-288. PubMed ID: 29983350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD).
    Png ME; Dritsaki M; Gray A; Pinedo-Villanueva R; Rivero-Arias O; Nanchahal J
    Wellcome Open Res; 2018; 3():156. PubMed ID: 30756094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study investigating the acceptability and design of a multicentre randomised controlled trial of needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren's contractures of the fingers (HAND-1): study protocol for a randomised controlled trial.
    Harrison E; Tan W; Mills N; Karantana A; Sprange K; Duley L; Elliott D; Blazeby J; Hollingworth W; Montgomery AA; Davis T
    Trials; 2017 Aug; 18(1):392. PubMed ID: 28841903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation model.
    Dakin H; Rombach I; Dritsaki M; Gray A; Ball C; Lamb SE; Nanchahal J
    Bone Jt Open; 2022 Nov; 3(11):898-906. PubMed ID: 36378072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments for early-stage Dupuytren's disease: an evidence-based approach.
    Nanchahal J; Chan JK
    J Hand Surg Eur Vol; 2023 Mar; 48(3):191-198. PubMed ID: 36638105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.
    Brazzelli M; Cruickshank M; Tassie E; McNamee P; Robertson C; Elders A; Fraser C; Hernandez R; Lawrie D; Ramsay C
    Health Technol Assess; 2015 Oct; 19(90):1-202. PubMed ID: 26524616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupuytren's disease. A model for the mechanism of fibrosis and its modulation by steroids.
    Meek RM; McLellan S; Crossan JF
    J Bone Joint Surg Br; 1999 Jul; 81(4):732-8. PubMed ID: 10463754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipose-derived stem cells inhibit the contractile myofibroblast in Dupuytren's disease.
    Verhoekx JSN; Mudera V; Walbeehm ET; Hovius SER
    Plast Reconstr Surg; 2013 Nov; 132(5):1139-1148. PubMed ID: 23924646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
    Bianchi E; Taurone S; Bardella L; Signore A; Pompili E; Sessa V; Chiappetta C; Fumagalli L; Di Gioia C; Pastore FS; Scarpa S; Artico M
    Clin Sci (Lond); 2015 Oct; 129(8):711-20. PubMed ID: 26201022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica.
    Williams NH; Jenkins A; Goulden N; Hoare Z; Hughes DA; Wood E; Foster NE; Walsh DA; Carnes D; Sparkes V; Hay EM; Isaacs J; Konstantinou K; Morrissey D; Karppinen J; Genevay S; Wilkinson C
    Health Technol Assess; 2017 Oct; 21(60):1-180. PubMed ID: 29063827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme injection as nonsurgical treatment of Dupuytren's disease.
    Badalamente MA; Hurst LC
    J Hand Surg Am; 2000 Jul; 25(4):629-36. PubMed ID: 10913202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro.
    Moyer KE; Banducci DR; Graham WP; Ehrlich HP
    Plast Reconstr Surg; 2002 Jul; 110(1):187-93; discussion 194-6. PubMed ID: 12087251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feedback inhibition of high TGF-beta1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts.
    Wong M; Mudera V
    J Hand Surg Br; 2006 Oct; 31(5):473-83. PubMed ID: 16875762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myofibroblast in Dupuytren's contracture.
    Rudolph R; Vande Berg J
    Hand Clin; 1991 Nov; 7(4):683-92; discussion 693-4. PubMed ID: 1769990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three-armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren's contracture.
    Räisänen MP; Karjalainen T; Göransson H; Reito A; Kautiainen H; Malmivaara A; Leppänen OV
    BMJ Open; 2018 Mar; 8(3):e019054. PubMed ID: 29599391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.